Share on StockTwits

Biota Pharmaceuticals (NASDAQ:BOTA) EVP Joseph M. Patti acquired 5,000 shares of Biota Pharmaceuticals stock in a transaction dated Friday, June 27th. The stock was purchased at an average price of $2.81 per share, with a total value of $14,050.00. Following the acquisition, the executive vice president now directly owns 67,241 shares of the company’s stock, valued at approximately $188,947. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Biota Pharmaceuticals (NASDAQ:BOTA) opened at 2.85 on Tuesday. Biota Pharmaceuticals has a one year low of $2.35 and a one year high of $7.07. The stock has a 50-day moving average of $2.87 and a 200-day moving average of $4.63. The company’s market cap is $100.0 million.

Biota Pharmaceuticals (NASDAQ:BOTA) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.28) by $0.37. Analysts expect that Biota Pharmaceuticals will post $-0.22 EPS for the current fiscal year.

Separately, analysts at TheStreet downgraded shares of Biota Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 30th.

Biota Pharmaceuticals, Inc, formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.